These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 34214182)

  • 1. A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management.
    Joshi S; Tepper SJ; Lucas S; Rasmussen S; Nelson R
    Headache; 2021 Jun; 61(6):838-853. PubMed ID: 34214182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations.
    Lionetto L; Borro M; Curto M; Capi M; Negro A; Cipolla F; Gentile G; Martelletti P
    Expert Opin Drug Metab Toxicol; 2016; 12(4):399-406. PubMed ID: 26878379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments.
    Chua AL; Mehla S; Orlova YY
    Curr Pain Headache Rep; 2022 Jul; 26(7):493-504. PubMed ID: 35587859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
    Do TP; Al-Saoudi A; Ashina M
    Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive migraine treatment.
    Silberstein SD
    Neurol Clin; 2009 May; 27(2):429-43. PubMed ID: 19289224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
    Arca K; Reynolds J; Sands KA; Shiue HJ
    Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent Advances in the Management of Migraine in Older Patients.
    Soni PP; Lee M; Shadbehr N; Ahmed ZA
    Drugs Aging; 2020 Jul; 37(7):463-468. PubMed ID: 32578024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.
    Yuan H; White CS; Silberstein SD
    Clin Pharmacol Ther; 2019 May; 105(5):1121-1129. PubMed ID: 30648737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update.
    Tajti J; Szok D; Csáti A; Vécsei L
    Curr Pain Headache Rep; 2016 Jan; 20(1):1. PubMed ID: 26695061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Migraine preventive treatment.
    Silberstein SD
    Handb Clin Neurol; 2010; 97():337-54. PubMed ID: 20816433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments.
    Sternieri E; Coccia CP; Pinetti D; Guerzoni S; Ferrari A
    Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):981-1007. PubMed ID: 17125412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
    Cohen JM; Dodick DW; Yang R; Newman LC; Li T; Aycardi E; Bigal ME
    Headache; 2017 Oct; 57(9):1375-1384. PubMed ID: 28862758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine.
    Lupi C; Benemei S; Guerzoni S; Pellesi L; Negro A
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):189-198. PubMed ID: 30714429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Migraine preventive treatment: monoclonal antibodies against calcitonine gene related peptide].
    Goicochea MT; Bonamico L
    Medicina (B Aires); 2021; 81(3):427-431. PubMed ID: 34137704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CGRP Pathway in Migraine as a Viable Target for Therapies.
    Edvinsson L
    Headache; 2018 May; 58 Suppl 1():33-47. PubMed ID: 29697153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K; Michael RL; Rapoport AM
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.